

Author index*

A

- Abernethy DR (*see* Spyker et al). 2000;67:196-200 (Commentary)
 Ademowo OG, Sodeinde O, Walker O. The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus. 2000;67:237-41
 Affrime MB (*see* Gorski et al). 2000;67:32-43
 Akinoto M (*see* Furuya et al). 2000;67:489-97
 Allaire J (*see* Hamelin et al). 2000;67:466-77
 Allegra A (*see* Buemi et al). 2000;67:427-31
 Aloisi C (*see* Buemi et al). 2000;67:427-31
 Andersen MP (*see* Marbury et al). 2000;67:7-15
 Anderson GD (*see* Roby et al). 2000;67:451-7
 Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. 2000;67:44-7
 Arnold JMO (*see* Dzeka et al). 2000;67:299-304
 Arnold JMO (*see* Feng et al). 2000;67:292-8
 Atkinson AJ (*see* Spyker et al). 2000;67:196-200 (Commentary)
 Avram MJ (*see* Niemann et al). 2000;67:342-50
 Azie NE (*see* Fleishaker et al). 2000;67:498-503

B

- Backman JT, Mäenpää J, Belle DJ, Wrighton SA, Kivistö KT, Neuvonen PJ. Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation. 2000;67:382-90
 Backman JT (*see* Varis et al). 2000;67:215-21
 Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. 2000;67:689 (Letter)
 Banken L (*see* Jorga et al). 2000;67:610-20
 Bannon P (*see* Villeneuve et al). 2000;67:242-8
 Banyai M, Thalhammer F, El Menyawi I, Heinz G, Traunmüller F, Siostzonek P. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000;67:368-72
 Bastian G (*see* Isetta et al). 2000;67:323-5
 Baudouy M (*see* Isetta et al). 2000;67:323-5
 Beaune P (*see* Simon et al). 2000;67:432-7
 Becker P (*see* Gorski et al). 2000;67:32-43
 Becquemont L (*see* Simon et al). 2000;67:432-7
 Beijnen JH (*see* Huitema et al). 2000;67:621-30
 Belle DJ (*see* Backman et al). 2000;67:382-90
 Belpaire FM (*see* Hemeryck et al). 2000;67:283-92
 Benowitz NL, Jacob P. Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. 2000;67:653-9
 Benowitz NL (*see* Chalon et al). 2000;67:391-7
 Benowitz NL (*see* Dempsey et al). 2000;67:458-65
 Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. 2000;67:413-8
 Bernabei R (*see* Zuccalà et al). 2000;67:314-22
 Besner JG (*see* du Souich et al). 2000;67:249-57
 Blaak EE (*see* Schifflers et al). 2000;67:558-66
 Blachke TF (*see* Chalon et al). 2000;67:391-7

- Bokstein F (*see* Zylber-Katz et al). 2000;67:631-41
 Boruchoff SE, Sturgill MG, Grasing KW, Seibold JR, McCrea J, Winchell GA, Kusma SE, Deutsch PJ. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. 2000;67:351-9
 Bouayad A (*see* Hamelin et al). 2000;67:466-77
 Bouillon T (*see* Pollak et al). 2000;67:642-52
 Braeckman RA (*see* Kemme et al). 2000;67:504-11
 Brater DC, Daly WJ. Clinical pharmacology in the Middle Ages: principles that presage the 21st century. 2000;67:447-50 (Commentary)
 Brater DC (*see* Mousa et al). 2000;67:267-74
 Breddin HK (*see* Klinkhardt et al). 2000;67:305-13
 Brodde OE (*see* Jakubetz et al). 2000;67:549-57
 Brown NJ (*see* Xie et al). 2000;67:670-5
 Brunner M (*see* Hollenstein et al). 2000;67:229-36
 Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe MS, Pettinato G, Corsonello A, Senatore M, Frisina N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. 2000;67:427-31
 Burgraaf J (*see* Kemme et al). 2000;67:504-11
 Burri C (*see* Keiser et al). 2000;67:478-88
 Burstein AH (*see* Roby et al). 2000;67:451-7

C

- Caillé G (*see* du Souich et al). 2000;67:249-57
 Callow ID (*see* Feng et al). 2000;67:292-8
 Cantilena LR (*see* Spyker et al). 2000;67:196-200 (Commentary)
 Carbonin P (*see* Zuccalà et al). 2000;67:314-22
 Carel BJ (*see* Fleishaker et al). 2000;67:498-503
 Carosella L (*see* Zuccalà et al). 2000;67:314-22
 Cha JJ (*see* Yoon et al). 2000;67:567-76
 Cha YN (*see* Chung et al). 2000;67:258-66
 Cha YN (*see* Yoon et al). 2000;67:567-76
 Chalon S, Moreno H, Benowitz NL, Hoffman BB, Blachke TF. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. 2000;67:391-7
 Chien JY (*see* Thummel et al). 2000;67:591-9
 Childs A (*see* Kemme et al). 2000;67:504-11
 Cho MH (*see* Chung et al). 2000;67:258-66
 Chung WG, Kang JH, Park CS, Cho MH, Cha YN. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. 2000;67:258-66
 Clozel JP (*see* du Souich et al). 2000;67:249-57
 Cocchi A (*see* Zuccalà et al). 2000;67:314-22
 Cohen AF (*see* Kemme et al). 2000;67:504-11
 Corica F (*see* Buemi et al). 2000;67:427-31
 Corsonello A (*see* Buemi et al). 2000;67:427-31
 Crespi CL (*see* Sata et al). 2000;67:48-56
 Cutler DL (*see* Gorski et al). 2000;67:32-43

D

- Daily JP (*see* Greenblatt et al). 2000;67:335-41
 Daly WJ (*see* Brater and Daly). 2000;67:447-50 (Commentary)
 Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. 2000;67:530-7

*January, pp. 1-88; February, pp. 89-192; March, pp. 193-330; April, pp. 331-446; May, pp. 447-590; June, pp. 591-710. Index to the ASCPT meeting abstracts is located in the February issue.

- De Carolis MP (see Romagnoli et al). 2000;67:676-82
 de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. 2000;67:360-7
 De Maeght S (see Villeneuve et al). 2000;67:242-8
 De Vriendt C (see Hemeryck et al). 2000;67:283-92
 de Waziers I (see Simon et al). 2000;67:432-7
 DeBrot DJ (see Goldstein et al). 2000;67:419-26
 Delacher S (see Hollenstein et al). 2000;67:229-36
 Delogu AB (see Romagnoli et al). 2000;67:676-82
 Dempsey D, Jacob P, Benowitz NL. Nicotine metabolism and elimination kinetics in newborns. 2000;67:458-65
 Desgagnés P (see Hamelin et al). 2000;67:466-77
 Deutsch PJ (see Boruchoff et al). 2000;67:351-9
 Diener HC. Eletriptan and coronary artery. 2000;67:326 (Letter)
 Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. 2000;67:512-20
 Dishy V (see Xie et al). 2000;67:670-5
 Dobrev D (see Grossmann et al). 2000;67:22-31
 Dresser GK (see Bailey and Dresser). 2000;67:689 (Letter)
 Dryer DA (see Roby et al). 2000;67:451-7
 du Souich P, Besner JG, Clozel JP, Welker HA, Lefebvre M, Caillé G. Nonlinear kinetics and pharmacologic response to mibefradil. 2000;67:249-57
 Dumesnil J (see Hamelin et al). 2000;67:466-77
 Durol ALB (see Greenblatt et al). 2000;67:335-41
 Dzeka TN, Kuzminski P, Arnold JMO. Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin. 2000;67:299-304

E

- Ebert U, Oertel R, Kirch W. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. 2000;67:538-48
 Edsbäck S (see Seidegård et al). 2000;67:373-81
 Eichler HG (see Hollenstein et al). 2000;67:229-36
 El Menyawi I (see Banyai et al). 2000;67:368-72
 Elizondo G (see Sata et al). 2000;67:48-56
 Elliot C, Newman N, Madan A. Gentamicin effects on urinary electrolyte excretion in healthy subjects. 2000;67:16-21
 Enders-Klein C (see Niemann et al). 2000;67:342-50
 Engel J (see Erb et al). 2000;67:660-9
 Erb K, Pechstein B, Schueler A, Engel J, Hermann R. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study. 2000;67:660-9
 Eriesson Ö (see Keiser et al). 2000;67:478-88
 Erovic B (see Hollenstein et al). 2000;67:229-36

F

- Feely J, McGettigan P, Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. 2000;67:438-41
 Feng Q, Lambert ML, Callow ID, Arnold JMO. Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure. 2000;67:292-8
 Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. 2000;67:498-503
 Flockhart DA (see Benton et al). 2000;67:413-8
 Flockhart DA (see Yoon et al). 2000;67:567-76
 Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, Moss J (see Yuan et al). 2000;67:398-404
 Foss JF (see Yuan et al). 2000;67:398-404
 Fotteler B (see Jorga et al). 2000;67:610-20

- Frisina N (see Buemi et al). 2000;67:427-31
 Fujimura A (see Harada et al). 2000;67:405-12
 Funck-Brentano C (see Simon et al). 2000;67:432-7
 Furue H (see Takanaga et al). 2000;67:201-14
 Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T. Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. 2000;67:683-8
 Furuya A, Kato N, Jingu S, Akimoto M, Higuchi S, Suwa T, Ogata H. Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects. 2000;67:489-97

G

- Gainer JV (see Xie et al). 2000;67:670-5
 Garaffo R (see Isetta et al). 2000;67:323-5
 Giacobbe MS (see Buemi et al). 2000;67:427-31
 Gitter BD (see Goldstein et al). 2000;67:419-26
 Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrot DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. 2000;67:419-26
 Gomori JM (see Zylber-Katz et al). 2000;67:631-41
 Gonzalez FJ (see Sata et al). 2000;67:48-56
 Goree RE (see Xie et al). 2000;67:670-5
 Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. 2000;67:32-43
 Graf JA (see Greenblatt et al). 2000;67:335-41
 Graff J (see Klinkhardt et al). 2000;67:305-13
 Grasing KW (see Boruchoff et al). 2000;67:351-9
 Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI. Alprazolam-ritonavir interaction: implications for product labeling. 2000;67:335-41
 Grossmann M, Dobrev D, Himmel HM, Kirch W. Local venous response to *N*-desethylamiodarone in humans. 2000;67:22-31
 Grözinger M (see Härter et al). 2000;67:1-6
 Gruppo Italiano di Farmacoepidemiologia nell'Anziano (GIFA) investigators (see Zuccalà et al). 2000;67:314-22

H

- Haefeli WE (see Arnet and Haefeli). 2000;67:44-7
 Haehner-Daniels B (see Gorski et al). 2000;67:32-43
 Haines JL (see Xie et al). 2000;67:670-5
 Hall SD (see Gorski et al). 2000;67:32-43
 Hall SD (see Mousa et al). 2000;67:267-74
 Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J, Turgeon J. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. 2000;67:466-77
 Hanai H (see Furuta et al). 2000;67:683-8
 Harada K, Kawaguchi A, Ohmori M, Fujimura A. Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors. 2000;67:405-12
 Harder S (see Klinkhardt et al). 2000;67:305-13
 Harmatz JS (see Greenblatt et al). 2000;67:335-41
 Härter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. 2000;67:1-6
 Harvey AM (see Spyker et al). 2000;67:196-200 (Commentary)
 Harvey BE (see Spyker et al). 2000;67:196-200 (Commentary)
 Harvey ED (see Spyker et al). 2000;67:196-200 (Commentary)
 Hashiguchi M (see Shiga et al). 2000;67:222-8

- Hatorp V (see Marbury et al). 2000;67:7-15
Heinz G (see Banyai et al). 2000;67:368-72
Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. 2000;67:283-92
Henthorn TK (see Niemann et al). 2000;67:342-50
Hermann R (see Erb et al). 2000;67:660-9
Hiemke C (see Härtter et al). 2000;67:1-6
Higuchi S (see Furuya et al). 2000;67:489-97
Higuchi S (see Takanaga et al). 2000;67:201-14
Himmel HM (see Grossmann et al). 2000;67:22-31
Hochstein HD (see McMahon et al). 2000;67:70 (Letter)
Hoffman BB (see Chalon et al). 2000;67:391-7
Hoffman JL (see Greenblatt et al). 2000;67:335-41
Hofmann U (see Dilger et al). 2000;67:512-20
Hollenstein U, Brunner M, Mayer BX, Delacher S, Erovic B, Eichler HG, Müller M. Target site concentrations after continuous infusion and bolus injection of cefipime to healthy volunteers. 2000;67:229-36
Huang WC (see Marbury et al). 2000;67:7-15
Huitema ADR, Mathôt RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. 2000;67:621-30

I

- Irie S (see Takanaga et al). 2000;67:201-14
Isetta C, Garaffo R, Bastian G, Jourdan J, Baudouy M, Milano G. Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine. 2000;67:323-5
Ishizaki T (see Furuta et al). 2000;67:683-8
Iyengar S (see Goldstein et al). 2000;67:419-26

J

- Jacob P (see Benowitz and Jacob). 2000;67:653-9
Jacob P (see Dempsey et al). 2000;67:458-65
Jaillon P (see Simon et al). 2000;67:432-7
Jakubetz J, Schmuck S, Wochatz G, Ruhland B, Poller U, Radke J, Brodde OE. Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine. 2000;67:549-57
Jang JJ (see Yoon et al). 2000;67:567-76
Jilma B. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Reply)
Jingu S (see Furuya et al). 2000;67:489-97
Jobin J (see Hamelin et al). 2000;67:466-77
Jorga K, Banken L, Fotteler B, Snell P, Steimer JL. Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone. 2000;67:610-20
Jourdan J (see Isetta et al). 2000;67:323-5

K

- Kalhorn TF (see Manyike et al). 2000;67:275-82
Kang JH (see Chung et al). 2000;67:258-66
Kantor E (see Roby et al). 2000;67:451-7
Karim A (see Kemme et al). 2000;67:504-11
Karrison T (see Yuan et al). 2000;67:398-404
Kasanuki H (see Shiga et al). 2000;67:222-8
Kato N (see Furuya et al). 2000;67:489-97
Kawaguchi A (see Harada et al). 2000;67:405-12
Kawano K (see Takanaga et al). 2000;67:201-14
Keiser J, Ericsson Ö, Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. 2000;67:478-88

- Kelly A (see Feely et al). 2000;67:438-41
Kemme MJB, Burgaaf J, Schoemaker RC, Paulson S, Karim A, Lentjes EGWM, Childs A, Braeckman RA, Cohen AF. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. 2000;67:504-11
Kharasch ED (see Manyike et al). 2000;67:275-82
Kim KA (see Yoon et al). 2000;67:567-76
Kim RB (see Kinirons et al). 2000;67:577 (Reply)
Kim RB (see Xie et al). 2000;67:670-5
Kimura M (see Takanaga et al). 2000;67:201-14
Kinirons MT, O'shea D, Kim RB, Wood AJJ, Wilkinson GR. Erythromycin breath test. 2000;67:577 (Reply)
Kirch W (see Ebert et al). 2000;67:538-48
Kirch W (see Grossmann et al). 2000;67:22-31
Kirchmaier CM (see Klinkhardt et al). 2000;67:305-13
Kivistö KT (see Backman et al). 2000;67:382-90
Kivistö KT (see Varis et al). 2000;67:215-21
Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S. Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A. 2000;67:305-13
Klotz U (see Dilger et al). 2000;67:512-20
Kramer Nielsen K (see Marbury et al). 2000;67:7-15
Krejcie TC (see Niemann et al). 2000;67:342-50
Kuroiwa Y (see Nakajima et al). 2000;67:57-69
Kusma SE (see Boruchoff et al). 2000;67:351-9
Kuzminski P (see Dzeka et al). 2000;67:299-304

L

- Lambert ML (see Feng et al). 2000;67:292-8
L'Ecuyer L, De Maeght S, Bannon P (see Villeneuve et al). 2000;67:242-8
L'Ecuyer L (see Villeneuve et al). 2000;67:242-8
Lefebvre M (see du Souich et al). 2000;67:249-57
Lefebvre RA (see Hemeryck et al). 2000;67:283-92
Lentjes EGWM (see Kemme et al). 2000;67:504-11
Lossos A (see Zylber-Katz et al). 2000;67:631-41
Love MP (see Davie et al). 2000;67:530-7
Lown KE (see Thummel et al). 2000;67:591-9
Luciano R (see Romagnoli et al). 2000;67:676-82

M

- Madan A (see Elliot et al). 2000;67:16-21
Mäenpää J (see Backman et al). 2000;67:382-90
Mahnel R (see Klinkhardt et al). 2000;67:305-13
Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. 2000;67:275-82
Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Kramer Nielsen K, Huang WC, Strange P. Pharmacokinetics of repaglinide in subjects with renal impairment. 2000;67:7-15
Mary-Krause M (see Simon et al). 2000;67:432-7
Mathôt RAA (see Huitema et al). 2000;67:621-30
Matsukuma K (see Takanaga et al). 2000;67:201-14
Matsuo H (see Takanaga et al). 2000;67:201-14
Mayer BX (see Hollenstein et al). 2000;67:229-36
McCrea J (see Boruchoff et al). 2000;67:351-9
McGettigan P (see Feely et al). 2000;67:438-41
McMahon EG, Vargas R, Hochstein HD. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Letter)
McMurray JJV (see Davie et al). 2000;67:530-7
Merlé Y (see Tréluyer et al). 2000;67:600-9
Mertzanis P (see Greenblatt et al). 2000;67:335-41
Méthot J (see Hamelin et al). 2000;67:466-77

- Milano G (*see* Isetta et al). 2000;67:323-5
 Miller VP (*see* Sata et al). 2000;67:48-56
 Moreno H (*see* Chalon et al). 2000;67:391-7
 Moss J (*see* Yuan et al). 2000;67:398-404
 Mousa O, Brater DC, Sundblad KJ, Hall SD. The interaction of diltiazem with simvastatin. 2000;67:267-74
 Mouton JW (*see* de Hoog et al). 2000;67:360-7
 Müller M (*see* Hollenstein et al). 2000;67:229-36
 Murakami H (*see* Takanaga et al). 2000;67:201-14

N

- Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the *CYP2A6* gene in humans. 2000;67:57-69
 Nelson SD (*see* Thummel et al). 2000;67:591-9
 Neuvonen PJ (*see* Backman et al). 2000;67:382-90
 Neuvonen PJ (*see* Varis et al). 2000;67:215-21
 Newman N (*see* Elliot et al). 2000;67:16-21
 Niemann CU, Henthorn TK, Krejcie TC, Shanks CA, Enders-Klein C, Avram MJ. Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. 2000;67:342-50

O

- O'Connor M (*see* Yuan et al). 2000;67:398-404
 Oertel R (*see* Ebert et al). 2000;67:538-48
 Ogata H (*see* Furuya et al). 2000;67:489-97
 Ohashi K (*see* Furuta et al). 2000;67:683-8
 Ohmori M (*see* Harada et al). 2000;67:405-12
 Ohnishi A (*see* Takanaga et al). 2000;67:201-14
 Orii Y (*see* Takanaga et al). 2000;67:201-14
 O'shea D (*see* Kinirons et al). 2000;67:577 (Reply)
 Osinski J (*see* Yuan et al). 2000;67:398-404

P

- Pahor M (*see* Zuccalà et al). 2000;67:314-22
 Papacci P (*see* Romagnoli et al). 2000;67:676-82
 Park CS (*see* Chung et al). 2000;67:258-66
 Park CW (*see* Yoon et al). 2000;67:567-76
 Paulson S (*see* Kemme et al). 2000;67:504-11
 Pechstein B (*see* Erb et al). 2000;67:660-9
 Peck CC (*see* Spyker et al). 2000;67:196-200 (Commentary)
 Pedone C (*see* Zuccalà et al). 2000;67:314-22
 Pettinato G (*see* Buemi et al). 2000;67:427-31
 Piersigilli F (*see* Romagnoli et al). 2000;67:676-82
 Poirier P (*see* Hamelin et al). 2000;67:466-77
 Polimeni V (*see* Romagnoli et al). 2000;67:676-82
 Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. 2000;67:642-52
 Poller U (*see* Jakubetz et al). 2000;67:549-57
 Pons G (*see* Tréluyer et al). 2000;67:600-9

R

- Radke J (*see* Jakubetz et al). 2000;67:549-57
 Raunio H (*see* Sata et al). 2000;67:48-56
 Reidenberg MM. Are we treating health or physical appearance when we prescribe drugs for obesity? 2000;67:193-5 (Commentary)
 Rikihisa T (*see* Shiga et al). 2000;67:222-8
 Ro H (*see* Thummel et al). 2000;67:591-9
 Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH, St John's Wort: effect on CYP3A4 activity. 2000;67:451-7

- Rodenhuis S (*see* Huitema et al). 2000;67:621-30
 Roizen MF (*see* Yuan et al). 2000;67:398-404
 Romagnoli C, De Carolis MP, Papacci P, Polimeni V, Luciano R, Piersigilli F, Delogu AB, Tortorolo G. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. 2000;67:676-82
 Röschke J (*see* Härtter et al). 2000;67:1-6
 Ruckle JL (*see* Marbury et al). 2000;67:7-15
 Ruhland B (*see* Jakubetz et al). 2000;67:549-57
 Rumack BH (*see* Spyker et al). 2000;67:196-200 (Commentary)

S

- Sale M (*see* Benton et al). 2000;67:413-8
 Sapone A (*see* Sata et al). 2000;67:48-56
 Saris WHM (*see* Schiffelers et al). 2000;67:558-66
 Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. *CYP3A4* allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity. 2000;67:48-56
 Sawada Y (*see* Takanaga et al). 2000;67:201-14
 Schellens JHM (*see* Huitema et al). 2000;67:621-30
 Schiffelers SLH, Blaak EE, Saris WHM, van Baak MA. In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use. 2000;67:558-66
 Schmuck S (*see* Jakubetz et al). 2000;67:549-57
 Schoemaker RC (*see* de Hoog et al). 2000;67:360-7
 Schoemaker RC (*see* Kemme et al). 2000;67:504-11
 Schueler A (*see* Erb et al). 2000;67:660-9
 Schuster BG (*see* Wesche et al). 2000;67:521-9
 Schwartz A (*see* Zylber-Katz et al). 2000;67:631-41
 Seibold JR (*see* Boruchoff et al). 2000;67:351-9
 Seidegård J, Simonsson M, Edsbäcker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. 2000;67:373-81
 Semlali A (*see* Tréluyer et al). 2000;67:600-9
 Senatore M (*see* Buemi et al). 2000;67:427-31
 Shader RI (*see* Greenblatt et al). 2000;67:335-41
 Shafer SL (*see* Pollak et al). 2000;67:642-52
 Shanks CA (*see* Niemann et al). 2000;67:342-50
 Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. 2000;67:222-8
 Shin SG (*see* Yoon et al). 2000;67:567-76
 Shirai N (*see* Furuta et al). 2000;67:683-8
 Shon JH (*see* Yoon et al). 2000;67:567-76
 Siegal T (*see* Zylber-Katz et al). 2000;67:631-41
 Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C, Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. 2000;67:432-7
 Simonsson M (*see* Seidegård et al). 2000;67:373-81
 Siostrzonek P (*see* Banyai et al). 2000;67:368-72
 Sisson TA (*see* Fleishaker et al). 2000;67:498-503
 Slattery JT (*see* Manyike et al). 2000;67:275-82
 Slattery JT (*see* Thummel et al). 2000;67:591-9
 Snell P (*see* Jorga et al). 2000;67:610-20
 Sodeinde O (*see* Ademowo et al). 2000;67:237-41
 Sofowora G (*see* Xie et al). 2000;67:670-5
 Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ, Woosley RL, Ahernethy DR, Cantilena LR. Assessment and reporting of clinical pharmacology information in drug labeling. 2000;67:196-200 (Commentary)
 Steimer JL (*see* Jorga et al). 2000;67:610-20
 Stein CM (*see* Xie et al). 2000;67:670-5
 Stocker P (*see* Sata et al). 2000;67:48-56
 Strange P (*see* Marbury et al). 2000;67:7-15
 Sturgill MG (*see* Boruchoff et al). 2000;67:351-9

Sundblad KJ (*see* Mousa et al). 2000;67:267-74
Suwa T (*see* Furuya et al). 2000;67:489-97

T

Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furue H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. 2000;67:201-14
Takashima M (*see* Furuta et al). 2000;67:683-8
Tanaka T (*see* Takanaga et al). 2000;67:201-14
Thalhammer F (*see* Banyai et al). 2000;67:368-72
Thummel KE, Slatery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. 2000;67:591-9
Tibben MM (*see* Huitema et al). 2000;67:621-30
Todd LE (*see* Goldstein et al). 2000;67:419-26
Tortorolo G (*see* Romagnoli et al). 2000;67:676-82
Traunmüller F (*see* Banyai et al). 2000;67:368-72
Trélluyer JM, Merlé Y, Semlali A, Pons G. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. 2000;67:600-9
Turgeon J (*see* Hamelin et al). 2000;67:466-77

U

Urae A (*see* Shiga et al). 2000;67:222-8
Urae A (*see* Takanaga et al). 2000;67:201-14
Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. 2000;67:331-4 (Commentary)

V

van Baak MA (*see* Schifflers et al). 2000;67:558-66
van den Anker JN (*see* de Hoog et al). 2000;67:360-7
Vargas R (*see* McMahon et al). 2000;67:70 (Letter)
Varis T, Backman JT, Kivistö KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. 2000;67:215-21
Villeneuve JP, L'Ecuyer L, De Maeght S, Bannon P. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe. 2000;67:242-8
von Moltke LL (*see* Greenblatt et al). 2000;67:335-41

W

Walker O (*see* Ademowo et al). 2000;67:237-41
Wang O (*see* Goldstein et al). 2000;67:419-26

Wang WX (*see* Wesche et al). 2000;67:521-9
Watkins PB. Erythromycin breath test. 2000;67:577 (Letter)
Watkins PB (*see* Thummel et al). 2000;67:591-9
Weigmann H (*see* Härtter et al). 2000;67:1-6
Welker HA (*see* du Souich et al). 2000;67:249-57
Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. 2000;67:521-9
Westrup D (*see* Klinkhardt et al). 2000;67:305-13
Wilkinson GR (*see* Kinirons et al). 2000;67:577 (Reply)
Winchell GA (*see* Boruchoff et al). 2000;67:351-9
Wochatz G (*see* Jakubetz et al). 2000;67:549-57
Wood AJJ (*see* Kinirons et al). 2000;67:577 (Reply)
Wood AJJ (*see* Xie et al). 2000;67:670-5
Woosley RL (*see* Benton et al). 2000;67:413-8
Woosley RL (*see* Spyker et al). 2000;67:196-200 (Commentary)
Woosley RL (*see* Wesche et al). 2000;67:521-9
Wrighton SA (*see* Backman et al). 2000;67:382-90

X

Xiao F (*see* Furuta et al). 2000;67:683-8
Xie HK, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, Brown NJ, Gore RE, Haines JL, Wood AJJ. Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. 2000;67:670-5

Y

Yamagishi S (*see* Nakajima et al). 2000;67:57-69
Yamamoto H (*see* Nakajima et al). 2000;67:57-69
Yamamoto T (*see* Nakajima et al). 2000;67:57-69
Yokoi T (*see* Nakajima et al). 2000;67:57-69
Yoon YR, Cha JJ, Shon JH, Kim KA, Cha YN, Jang JJ, Park CW, Shin SG, Flockhart DA. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. 2000;67:567-76
Yuan CS, Foss JF, O'Connor M, Karrison T, Osinski J, Roizen MF, Moss J. Effects of enteric-coated methylaltrexone in preventing opioid-induced delay in oral-cecal transit time. 2000;67:398-404

Z

Zheng W (*see* Sata et al). 2000;67:48-56
Zuccalà G, Pedone C, Cocchi A, Pahor M, Carosella L, Carboni P, Bernabei R. Gruppo Italiano di Farmacoepidemiologia nell'Anziano (GIFA) investigators. Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study. 2000;67:314-22
Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. 2000;67:631-41

Subject index*

A

Abciximab

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Acetaminophen

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9

Adrogolide hydrochloride

Adrogolide hydrochloride (USAN List No. 423). 2000;67:74

Age factors

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Aged

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccalà et al). 2000;67:314-22

Alemcinal

Alemcinal (USAN List No. 423). 2000;67:74

Almotriptan

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503

Alprazolam

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

American Society for Clinical Pharmacology and Therapeutics

Abstract of annual meeting. 2000;67:89-192

Annual meeting program. 2000;67:79-87

New website announcement. 2000;67:328

New members of the Society. 2000;67:582

2000 Annual meeting abstract books announcement. 2000;67:584

2000 Annual meeting audiocassettes announcement. 2000;67:585

2000-2001 Officers, committee chairpersons, and board members. 2000;67:690

Call for scientific program abstracts. 2000;67:691

Amiloxate

Amiloxate (USAN List No. 423). 2000;67:75

Amiodarone

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31

Population pharmacokinetics of long-term oral amiodarone therapy (Pollak et al). 2000;67:642-52

Amoxicillin

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Analgesics, non-narcotic

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70

Antibiotics, aminoglycoside

Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21

Antihistamines

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Aspirin

Antipyretic efficacy of aspirin or acetaminophen (McMahon et al) (Letter); (Jilma) (Reply). 2000;67:70

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin (Dzeka et al). 2000;67:299-304

Authorship

The forgotten author. 2000;67:326 (Letter)

B

Bayes theorem

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods (Huiteima et al). 2000;67:621-30

Blood flow velocity

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor (Kemmerle et al). 2000;67:504-11

Blood volume

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

Body image

Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Brain

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Brain neoplasms

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Budesonide

Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol (Seidegård et al). 2000;67:373-81

*January, pp. 1-88; February, pp. 89-192; March, pp. 193-330; April, pp. 331-446; May, pp. 447-590; June, pp. 591-710. Index to the ASCPT meeting abstracts is located in the February issue.

C

Caffeine

Effect of age and smoking on *in vivo* CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Calcium channel blockers

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccalà et al). 2000;67:314-22

Carbamates

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Carbon monoxide

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Carboplatin

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods (Huitema et al). 2000;67:621-30

Cardiovascular system

Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5

Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9

Cefpirome

Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000;67:368-72

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers (Hollenstein et al). 2000;67:229-36

Cerebrospinal fluid

Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Chloroquine

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Chronotherapy

Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Cimetidine

Effect of cimetidine and probenecid on pilsicainide renal clearance in humans (Shiga et al). 2000;67:222-8

Clarithromycin

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin (Boruchoff et al). 2000;67:351-9

Clopidogrel

Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A (Klinkhardt et al). 2000;67:305-13

Commentaries

Commentaries. 2000;67:193-200, 447-50

Contraceptives, oral

Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol (Seidegård et al). 2000;67:373-81

Coronary arteries

Eletriptan and coronary artery (Diener). 2000;67:326 (Letter)

Corrections

Correction to Lewis et al. "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction." Vol 62, 1997, pages 464-75. 2000;67:431

Correction to Tan et al. "Vanadate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects." Vol 6, 1999, pages 275-81. 2000;67:367

Cotinine

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Crofelemer

Crofelemer (USAN List No. 423). 2000;67:76

Cyclosporine

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Cytochrome P-450

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82

CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56

Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (Nakajima et al). 2000;67:57-69

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

St. John's Wort: effect on CYP3A4 activity (Roby et al). 2000;67:451-7

In vivo effects of interleukin-10 on human cytochrome P450 activity (Gorski et al). 2000;67:32-43

Cytochrome P-450 CYP1A2

Effect of age and smoking on *in vivo* CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Cytochrome P-450 CYP2C19

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Cytochrome P-450 CYP2D6

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Cytochrome P-450 CYP2E1

Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation (Manyike et al). 2000;67:275-82

D

Desethylchloroquine

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Diltiazem

Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone (Varis et al). 2000;67:215-21

- The interaction of diltiazem with simvastatin (Mousa et al). 2000; 67:267-74
- Diphenhydramine**
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77
- Docosanol**
Docosanol (USAN List No. 424). 2000;67:330
- Drug administration**
Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. 2000; 67:368-72
Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers (Hollenstein et al). 2000;67:229-36
- Drug antagonism**
Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12
- Drug delivery systems**
Erratic patient compliance with prescribed drug regimens: target for drug delivery systems (Urquhart). 2000;67:331-4 (Commentary)
- Drug information**
Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)
- Drug interactions**
Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41
The interaction of diltiazem with simvastatin (Mousa et al). 2000;67:267-74
Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77
- Drug labeling**
Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41
Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)
- Drug toxicity**
Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9
Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5
Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9
- Duodenal ulcer**
Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8
- E**
- Electroencephalography**
Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48
- Electrolytes**
Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21
- Eletriptan**
Eletriptan and coronary artery (Diener). 2000;67:326 (Letter)
Eletriptan hydrobromide (USAN List No. 423). 2000;67:73
- Entecavir**
Entecavir (USAN List No. 424). 2000;67:329
- Enzacamene**
Enzacamene (USAN List No. 423). 2000;67:72
- Erythromycin**
Erythromycin breath test (Watkins) (Letter); (Kinirons et al) (Reply) 2000;67:577
- Ethanol**
Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9
- Evernimicin**
Evernimicin (USAN List No. 426). 2000;67:588
- Exatecan mesylate**
Exatecan mesylate (USAN List No. 424). 2000;67:329
- Exons**
CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56
- Ezlopitant**
Ezlopitant (USAN List No. 424). 2000;67:330
- F**
- Fiduxosin hydrochloride**
Fiduxosin hydrochloride (USAN List No. 424). 2000;67:330
- Fluorocytosine**
Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5
- Fluorouracil**
Life-threatening 5-fluorouracil-like cardiac toxicity after treatment with 5-fluorocytosine (Isetta et al). 2000;67:323-5
- Fluvastatin**
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31
- Fluvoxamine**
Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6
- Food-drug interactions**
Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)
- Fulvestrant**
Fulvestrant (USAN List No. 423). 2000;67:75
- G**
- Gemifloxacin mesylate**
Gemifloxacin mesylate (USAN List No. 423). 2000;67:72
- Gene deletion**
Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (Nakajima et al). 2000;67:57-69
- Gentamicins**
Gentamicin effects on urinary electrolyte excretion in healthy subjects (Elliot et al). 2000;67:16-21
- Glomerulonephritis, IGA**
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31
- Glutathione transferases**
Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7

Glycoproteins

Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects (Furuya et al). 2000;67:489-97

Gonads

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Grapefruit juice

Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects (Takanaga et al). 2000;67:201-14

H

Halofantrine

Mechanism of cardiotoxicity of halofantrine (Wesche et al). 2000;67:521-9

Health

Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Heart failure

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure (Feng et al). 2000;67:292-8

Helicobacter pylori

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Hemoglobin

Use of calcium antagonists and hemoglobin loss in hospitalized elderly patients: a cohort study (Zuccalà et al). 2000;67:314-22

History of Medicine, Medieval

Clinical pharmacology in the Middle Ages: principles that presage the 21st century (Brater and Daly). 2000;67:447-50 (Commentary)

Homosalate

Homosalate (USAN List No. 423). 2000;67:73

Hydroxylases

CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity (Sata et al). 2000;67:48-56

Hypertension

Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5

Hypoglycemic agents

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

I

Ibritumomab tiuxetan

Ibritumomab tiuxetan (USAN List No. 426). 2000;67:587

Ibuprofen

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Immunoglobulins, gamma-Chain

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Indinavir

The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin (Boruchoff et al). 2000;67:351-9

Indocyanine

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50

Infant, newborn

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Nicotine metabolism and elimination kinetics in newborns (Dempsey et al). 2000;67:458-65

Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method (Tréluyer et al). 2000;67:600-9

Vancomycin population pharmacokinetics in neonates (de Hoog et al). 2000;67:360-7

Insulin

Insulin detemir (USAN List No. 426). 2000;67:589

Interleukin-10

In vivo effects of interleukin-10 on human cytochrome P450 activity (Gorski et al). 2000;67:32-43

Iron sucrose

Iron sucrose (USAN List No. 426). 2000;67:587

Izonsteride

Izonsteride (USAN List No. 425). 2000;67:445

K

Kidney diseases

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Kidneys

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Korea

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76

L

Lanepitant

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

Lasofloxifene tartrate

Lasofloxifene tartrate (USAN List No. 425). 2000;67:443

Leflunomide

Leflunomide (USAN List No. 426). 2000;67:590

Letters to the Editor

Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. 2000;67:689 (Letter)

Diener HC. Eletriptan and coronary artery. 2000;67:326 (Letter)

- McMahon EG, Vargas R, Hochstein HD. Antipyretic efficacy of aspirin or acetaminophen. 2000;67:70 (Letter)
Watkins PB. Erythromycin breath test. 2000;67:577 (Letter)

Levodopa

- Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Liatermin

- Liatermin (USAN List No. 426). 2000;67:589

Lipids

- In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Liver

- Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7
Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults (Thummel et al). 2000;67:591-9
The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor (Kemmer et al). 2000;67:504-11

Liver transplantation

- Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Lovastatin

- Grapefruit juice-lovastatin interaction (Bailey and Dresser). 2000;67:689 (Letter)

Lymphoma

- Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

M**Maxacalcitol**

- Maxacalcitol (USAN List No. 426). 2000;67:590

Melarsoprol

- Investigations of the metabolites of the trypanocidal drug melarsoprol (Keiser et al). 2000;67:478-88

Melatonin

- Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6

Mequinol

- Mequinol (USAN List No. 425). 2000;67:443

Meradimate

- Meradimate (USAN List No. 423). 2000;67:73

Methotrexate

- Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma (Zylber-Katz et al). 2000;67:631-41

Methylnaltrexone

- Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time (Yuan et al). 2000;67:398-404

Metoprolol

- Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Hemeryck et al). 2000;67:283-292
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76
Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity (Hamelin et al). 2000;67:466-77

Mibefradil

- Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone (Varis et al). 2000;67:215-21
Nonlinear kinetics and pharmacologic response to mibefradil (du Souich et al). 2000;67:249-57

Midazolam

- Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90
Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48
Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe (Villeneuve et al). 2000;67:242-8

Motexafin gadolinium

- Motexafin gadolinium (USAN List No. 425). 2000;67:445

Motexafin lutetium

- Motexafin lutetium (USAN List No. 425). 2000;67:444

Moxonidine

- Moxonidine (USAN List No. 425). 2000;67:445

N**Nadolol**

- In vivo β_3 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Netilmicin

- Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method (Tréluyer et al). 2000;67:600-9

Nicotine

- Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (Nakajima et al). 2000;67:57-69
Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9
Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Nisoldipine

- Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects (Takanaga et al). 2000;67:201-14

Nonacog alfa

- Nonacog alfa (USAN List No. 426). 2000;67:588

Norepinephrine

- Venous responsiveness to norepinephrine in healthy subjects: effects of single doses of 325 mg aspirin (Dzeka et al). 2000;67:299-304

O**Obesity**

- Are we treating health or physical appearance when we prescribe drugs for obesity? (Reidenberg). 2000;67:193-5 (Commentary)

Octinoxate

- Octinoxate (USAN List No. 423). 2000;67:74

Octisalate

- Octisalate (USAN List No. 423). 2000;67:75

Olanexidine hydrochloride

- Olanexidine hydrochloride (USAN List No. 427). 2000;67:694

Omeprazole

Cure of refractory duodenal ulcer and infection caused by *Helicobacter pylori* by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient (Furuta et al). 2000;67:683-8

Opioids

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time (Yuan et al). 2000;67:398-404

Oseltamivir phosphate

Oseltamivir phosphate (USAN List No. 427). 2000;67:694

Osteoarthritis

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

P

Pain

Study of the analgesic effect of lanepitant in patients with osteoarthritis pain (Goldstein et al). 2000;67:419-26

Pantoprazole sodium

Pantoprazole sodium (USAN List No. 427). 2000;67:694

Parkinson disease

Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Paroxetine

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Hemeryck et al). 2000;67:283-292
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (Yoon et al). 2000;67:567-76

Patient compliance

Erratic patient compliance with prescribed drug regimens: target for drug delivery systems (Urquhart). 2000;67:331-4 (Commentary)
Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

Perflexane

Perflexane (USAN List No. 425). 2000;67:444

Perflutren

Perflutren (USAN List No. 425). 2000;67:444

Pharmacology, clinical

Assessment and reporting of clinical pharmacology information in drug labeling (Spyker et al). 2000;67:196-200 (Commentary)
Clinical pharmacology in the Middle Ages: principles that presage the 21st century (Brater and Daly). 2000;67:447-50 (Commentary)

Physostigmine

Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects (Ebert et al). 2000;67:538-48

Piboserod hydrochloride

Piboserod hydrochloride (USAN List No. 427). 2000;67:695

Pibrozelesin hydrobromide

Pibrozelesin hydrobromide (USAN List No. 427). 2000;67:695

Piliscainide

Effect of cimetidine and probenecid on piliscainide renal clearance in humans (Shiga et al). 2000;67:222-8

Piperidines

Pharmacokinetics of repaglinide in subjects with renal impairment (Marbury et al). 2000;67:7-15

Pirenzepine

Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Pituitary gland

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Polymorphism (genetic)

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7
Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5

Posaconazole

Posaconazole (USAN List No. 427). 2000;67:693

Prinomastat

Prinomastat (USAN List No. 427). 2000;67:693

Probenecid

Effect of cimetidine and probenecid on piliscainide renal clearance in humans (Shiga et al). 2000;67:222-8

Propafenone

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20

Prophylaxis

Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates (Romagnoli et al). 2000;67:676-82

Propranolol

Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol (Niemann et al). 2000;67:342-50
In vivo β_2 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Proteinuria

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy (Buemi et al). 2000;67:427-31

Pruritus

The disposition of chloroquine and its main metabolite desethylchloroquine in volunteers with and without chloroquine-induced pruritus: evidence for decreased chloroquine metabolism in volunteers with pruritus (Ademowo et al). 2000;67:237-41

Q

Quinidine

Greater quinidine-induced QTc interval prolongation in women (Benton et al). 2000;67:413-8

R

Receptors, adrenergic

Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12
Human cardiac β_1 - or β_2 -adrenergic receptor stimulation and the negative chronotropic effect of low-dose pirenzepine (Jakubetz et al). 2000;67:549-57

Receptors, adrenergic, beta

Human β_2 -adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans (Xie et al). 2000;67:670-5
In vivo β_2 -adrenergic stimulation of human thermogenesis and lipid use (Schiffelers et al). 2000;67:558-66

Receptors, neuropeptide Y

Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure (Feng et al). 2000;67:292-8

Rifampin

Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone (Dilger et al). 2000;67:512-20

Ritonavir

Alprazolam-ritonavir interaction: implications for product labeling (Greenblatt et al). 2000;67:335-41

Rivastigmine

Rivastigmine (USAN List No. 426). 2000;67:588

S**Self administration**

Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

Serotonin uptake inhibitors

Increased bioavailability of oral melatonin after fluvoxamine coadministration (Härtter et al). 2000;67:1-6

Simvastatin

The interaction of diltiazem with simvastatin (Mousa et al). 2000;67:267-74

Smoking

Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism (Chung et al). 2000;67:258-66

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism (Benowitz and Jacob). 2000;67:653-9

Statins

Growth in use of statins after trials is not targeted to most appropriate patients (Feely et al). 2000;67:438-41

Systole

Greater quinidine-induced QTc interval prolongation in women (Benton et al). 2000;67:413-8

T**Tacrine**

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity (Simon et al). 2000;67:432-7

Tamsulosin

Antagonistic activity of tamsulosin against human vascular α_1 -adrenergic receptors (Harada et al). 2000;67:405-12

Tangeretin

Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90

Tangerine juice

Lack of correlation between in vitro and in vivo studies on the effects on tangeretin and tangerine juice on midazolam hydroxylation (Backman et al). 2000;67:382-90

Tegaserod

Tegaserod (USAN List No. 427). 2000;67:696

Tesmilifene hydrochloride

Tesmilifene hydrochloride (USAN List No. 427). 2000;67:695

Teverelix

Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men—a first-dose-in-humans study (Erb et al). 2000;67:660-9

Time factors

Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisdipine in healthy subjects (Takanaga et al). 2000;67:201-14

Tolcapone

Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone (Jorga et al). 2000;67:610-20

Troxacitabine

Troxacitabine (USAN List No. 427). 2000;67:696

U**United States Adopted Names Council**

USAN Council. 2000;67:72-8, 329-30, 443-5, 587-90, 693-6

V**Vancomycin**

Vancomycin population pharmacokinetics in neonates (de Hoog et al). 2000;67:360-7

Vofopitant dihydrochloride

Vofopitant dihydrochloride (USAN List No. 427). 2000;67:696

Vasodilation

Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. (Davie et al). 2000;67:530-7

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31

Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Veins

Local venous response to *N*-desethylamiodarone in humans (Grossmann et al). 2000;67:22-31

Nicotine impairs endothelium-dependent dilatation in human veins in vivo. (Chalon et al). 2000;67:391-7

Verapamil

Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers (Fleishaker et al). 2000;67:498-503

Vitamins

Overconsumption detected by electronic drug monitoring requires subtle interpretation (Arnet and Haefeli). 2000;67:44-7

